Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size, Share, Trend, Outlook, Future Growth Analysis And Synthesis 2018 - 2026 Vascular Endothelial Growth Factor (VEGF) is a signal protein that helps in the formation of new blood vessels through a process known as angiogenesis. Vascular endothelial growth factor is a part of several pathological processes and researches are often carried out for the development of novel therapies using these factors for diseases such as cancer. Normal functions of vascular endothelial growth factor includes embryonic development, formation of new blood vessels, and as a bypass for a blocked vessel. However, overexpression of VEGF often culminates into fatal disease such as cancerous cells. As solid tumors require additional blood supply in order to keep functioning, the overexpression of VEGF serves that purpose through angiogenesis. VEGF family has five members such as VEGF-A, VEGF-B, VEGF-C, VEGFD, and Placenta Growth Factor (PGF). Out of these growth factors, VEGF-A is responsible for angiogenesis and processes associated with endothelial cells. VEGF-A binds to VEGF receptors on the endothelial cells, which triggers a tyrosine kinase pathway leading to angiogenesis. VEGF-A has been found to be associated with poor prognosis in various cancers, diabetic retinopathy, and age-related macular degeneration. Therapeutic agents are developed to inhibit the transduction pathways of vascular endothelial growth factor (VEGF). Drugs such as monoclonal antibodies against VEGF and tyrosine kinase inhibitors inhibit the angiogenesis process and disease progression. Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/1614 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Drivers Rising prevalence of diseases such as cancer and macular degeneration is expected to boost growth of the market over the forecast period. According to the American Cancer Society, in 2017, cancer was the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths. Novel therapies such as monoclonal antibodies and angiogenesis inhibitors are highly specialized targeted therapies, which directly targets the cancerous cells. The preference for targeted therapies is rising, owing to the advantages (lesser side effects) offered by targeted therapies over conventional therapies such as chemotherapy. Furthermore, robust pipeline of VEGF antibodies is expected to boost the market growth over the forecast period. For instance, Brolucizumab (Alcon) is in phase 3 clinical trials, Abicipar (Allergan Plc) is in phase 3 trials, and RG7716 (Genentech) is in phase 2 trials, all indicated for agerelated macular degeneration. Vascular Endothelial Growth Factor (VEGF) Antibodies Market Insights On the basis of region, North America and Europe are expected to show significant growth in the vascular endothelial growth factor antibodies market over the forecast period. North America has the presence of leading manufacturers who are indulged in research and development of these therapies. Manufacturers such as Novartis (Europe) and Genentech have these therapies in pipeline and are expected to enter into the market over the forecast period. Asia Pacific region is expected to show modest growth, owing to high costs of these therapies and fairly low availability overall the region. Sophisticated insurance facilities such as Medicaid and Medicare are not present in the developing economies due to which patients cannot afford costly medical treatment in these regions. However, insurance facilities are expected to drive growth of the market in North America. Report includes chapters which deeply display the following deliverable about industry : • Vascular Endothelial Growth Factor (VEGF) Antibodies Market Research Objective and Assumption • Vascular Endothelial Growth Factor (VEGF) Antibodies Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Vascular Endothelial Growth Factor (VEGF) Antibodies Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market, By Regions • Vascular Endothelial Growth Factor (VEGF) Antibodies Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Vascular Endothelial Growth Factor (VEGF) Antibodies Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Vascular Endothelial Growth Factor (VEGF) Antibodies Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Vascular Endothelial Growth Factor (VEGF) Antibodies Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Vascular Endothelial Growth Factor (VEGF) Antibodies Market – Key Players Key players operating in the vascular endothelial growth factor (VEGF) antibodies market include Genentech, Inc., Novartis, Exelixis, Inc., Eli Lilly and Company, Bayer Pharma AG, Regeneron Pharmaceuticals, Inc., Valeant Pharmaceuticals, Ceres Oncology Pty Ltd, and ThromboGenics, Inc. Vascular Endothelial Growth Factor (VEGF) Antibodies Market Taxonomy The global vascular endothelial growth factor (VEGF) antibodies market is segmented on the basis of drug, route of administration, application, distribution channel, and geography. By Drug - • Avastin • Tecentriq • Cometriq • Eylea • Jetrea • Cyramza • Macugen • Lucentis • Others By Application- • Cancer • Ophthalmology • Others Browse In-Depth Analysis Research Report @ https://www.coherentmarketinsights.com/ongoinginsight/vascular-endothelial-growth-factor-antibodies-market-1614 About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com
Rising prevalence of diseases such as cancer and macular degeneration is expected to boost growth of the market over the forecast period.
© Copyright 2024 Paperzz
